QUEBEC, Oct. 3, 2012 /CNW Telbec/ - The BioContact Quebec's symposium officially begins today at the Château Laurier in Quebec City. For two days, this platform of discussions on the topic of "biopharmaceutical partnership" is a structured approach to personalised meetings between biopharmaceutical and pharmaceutical companies, universities, consulting firms, venture capital companies and government representatives.
This year, the 18th edition of BioContact Quebec will give rise to several business meetings. "In a world where economical and demographical stakes are high and new challenges focus on the development of new and more targeted drugs associated with personalized health care, the discussion are sure to be lively and interesting during this 18th edition of BioContact Quebec", confirmed Mr. Martin Godbout, President of the event.
On the Agenda this Wednesday October 3rd, 2012
Many conferences on topics as varied as the development of new drugs against cancer, infectious and metabolic diseases, as well as the development of new medical instruments to facilitate the controlled release of medication, are on the Agenda for this Wednesday. The role of investors (venture capital) and the importance of the large pharmaceutical companies will be one of the topics of discussion during this afternoon's plenary sessions, in order to better understand the new business model in this rapidly changing industry.
Please note the Opening Dinner with guest speaker Mr. Reid Leonard, Executive Director of Merck Venture Capital. Mr. Leonard will elaborate on the new business models of the pharmaceutical industry.
SOURCE: BIOCONTACT QUEBEC
For further information:
Hélène Turcotte, Pressroom Co-ordinator
BioContact Quebec 2012